Advancing age in patients with epithelial ovarian cancer is a risk factor for decreased survival. The exact cause is unknown but part of this may be due to less than adequate therapy for these patients. To optimize treatment, this paper presents the available data for therapy and my own approach in the management of this disease. For optimal outcomes, there also needs to be a close collaboration between subspecialists (gynecologic oncology, medical oncology, pathology) in all aspects of treatment planning. Progression-free and overall survival can be prolonged and patients' quality of life can be maintained with appropriate management.
Keywords: Carboplatin; Cisplatin; Elderly; Intraperitoneal; Ovarian cancer; Paclitaxel; Serous ovarian cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.